Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 6/20 | 0.37 |
| ▸ | CCNC | P24863 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | WNT1 | P04628 | 4/20 | 0.36 |
| ▸ | GSK3B | P49841 | 4/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10039321 | 0.83 | HDAC1 (0.41) | CCNCCDK8CYP2C9 | |
| SCHEMBL3234967 | 0.80 | CCNC (0.37) | WNT3ACCNCCDK8FLT3 | |
| SCHEMBL1966580 | 0.76 | RAB9A (0.41) | — | |
| SCHEMBL13458174 | 0.75 | HDAC1 (0.42) | CCNCCDK8CYP2C9NAMPT | |
| SCHEMBL10069093 | 0.72 | HDAC1 (0.44) | CYP2C9 | |
| SCHEMBL13458535 | 0.72 | CCNC (0.37) | WNT3ACCNCCDK8WNT1GSK3B | |
| SCHEMBL9976635 | 0.69 | ALDH1A1 (0.41) | — | |
| SCHEMBL3226196 | 0.68 | HDAC1 (0.44) | — | |
| SCHEMBL3226156 | 0.68 | HDAC1 (0.44) | — | |
| SCHEMBL3226812 | 0.67 | HDAC1 (0.45) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| WO-2010031708-A2 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | IL4I1, MKI67, ABL1 | WNT3A 3482/4885CCNC 92/4885CDK8 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.